IsomAb – a University of Nottingham spinout pioneering a new treatment for diabetics at risk of amputation – has raised £7.5 million. The company, which is based in Nottingham’s BioCity and employs six staff, focuses on the treatment of peripheral arterial disease (PAD), a relatively common condition where the arteries in the legs and feet … Continue reading Spinout develops treatment for diabetics at risk of amputation